Inactive Instrument

Cassiopea S.p.A.

SKIN

IT0005108359

Cassiopea S.P.A. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 28, 2020 at 01:00 am EDT

Cassiopea S.P.A. Announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced operating loss was EUR 1.888 million compared to EUR 3.547 million a year ago. Net loss was EUR 2.119 million compared to EUR 3.621 million a year ago. Basic loss per share was EUR 0.212 compared to EUR 0.362 a year ago.

Latest news about Cassiopea S.p.A.

Cassiopea S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Hyphens Pharma Pte. Ltd., Enters into Exclusive License and Supply Agreements with Cassiopea S.p.A. for Exclusive Rights to Develop and Commercialize Winlevi in 10 Countries Across Southeast Asia	22-12-20	CI
Cassiopea Gets SIX Swiss Exchange Nod to Delist After Cosmo Pharmaceuticals Buyback	22-02-25	MT
Cassiopea To Delist From Swiss Bourse In March After Takeover By Cosmo Pharmaceuticals	22-02-04	MT
Cassiopea to Delist Shares from Swiss Bourse After Takeover by Cosmo	22-01-20	MT
Cosmo Closes Public Exchange Offer For Cassiopea After Amassing 97% Stake	21-12-17	MT
Cosmo Pharmaceuticals Secures Over 93% Stake in Cassiopea at Tender Closing	21-12-03	MT
Cassiopea S.p.A.(SWX:SKIN) dropped from Swiss Performance Index (Price Return)	21-12-03	CI
Cosmo Pharmaceuticals N.V. completed the acquisition of an additional 49.9% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 160 million.	21-12-01	CI
Cosmo Pharmaceuticals to Start Additional Acceptance Period in Cassiopea Offer	21-11-18	MT
Cosmo Pharmaceuticals Wins Shareholders Nod For Cassiopea Stake Deal	21-11-16	MT
Cosmo Pharmaceuticals Raises Cassiopea Stake To Over 87%	21-11-16	MT
Cassiopea's Partner Launches Winlevi Acne Treatment In US	21-11-03	MT
Cosmo Pharmaceuticals N : Initiates Public Exchange Offer For Cassiopea	21-10-04	MT
Cosmo Pharmaceuticals Intends to Acquire Cassiopea	21-10-03	CI
Cosmo Pharmaceuticals N.V. made an offer to acquire remaining 53.4% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 210 million.	21-10-03	CI
Cassiopea S p A : Female Androgenetic Alopecia Treatment Shows Improvement in Mid-Stage Trial	21-09-10	MT
Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Females	21-09-10	CI
Cassiopea S p A : Concludes License, Supply Deal for Acne Drug Winlevi	21-08-31	MT
Cassiopea S p A : H1 Loss Swells to $7 Million	21-07-29	MT
Cassiopea S.p.A. Provides Earnings Guidance for the Year 2021	21-07-29	CI
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada	21-07-26	CI
Cassiopea S p A : Enters License, Supply Deals for Acne Treatment in North America	21-07-26	MT
Sun Pharmaceutical Industries Ltd. and Cassiopea SpA Announces the Signing of License and Supply Agreements for Winlevi® (Clascoterone Cream 1%) in the United States and Canada	21-07-26	CI
Cassiopea S.P.A. Announces Board Changes	21-04-29	CI

Chart Cassiopea S.p.A.

Duration

Period

More charts

Company Profile

Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is on the topical treatment of acne, androgenic alopecia (''AGA'') and genital warts. Its portfolio comprises four clinical candidates, such as Winlevi, Breezula, CB-06-01 and CB-06-02, for which the Company owns the worldwide rights. These product candidates are based on three chemical entities (''NCE''). They target unmet medical needs and addressable opportunities in the medical dermatology market. The main shareholder of the Company is Cosmo Pharmaceuticals SA.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+3.82%	69.91B
KYOWA KIRIN CO. LTD.	+10.97%	9.03B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.31B
YUHAN CORPORATION	+3.92%	3.88B
INDIVIOR PLC	+16.88%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.70%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.98B

Specialty & Advanced Pharmaceuticals